We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B Turnover 10.26%
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
-8.83%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$3.57B
AUM Growth
-$614M
Cap. Flow
+$51.4M
Cap. Flow %
1.44%
Top 10 Hldgs %
48.82%
Holding
78
New
14
Increased
15
Reduced
33
Closed
9
Avg Time Held
1.3 years
Top 10 Avg Time Held
1.1 years
Top 20 Avg Time Held
0.9 years

Top Buys

Rank Stock Value
1
BEAM icon
Beam Therapeutics
BEAM
+$73M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$72.6M
3
ONEM
1Life Healthcare
ONEM
+$68.5M
4
MRK icon
Merck
MRK
+$64.9M
5
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$53.9M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$116M
2
FTSV
Forty Seven, Inc. Common Stock
FTSV
+$109M
3
BSX icon
Boston Scientific
BSX
+$73.8M
4
CNC icon
Centene
CNC
+$44.2M
5
HCA icon
HCA Healthcare
HCA
+$42.2M

Sector Composition

Rank Sector Weight
1 Healthcare 98.88%
2 Industrials 0.87%
3 Miscellaneous 0.25%
4 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
FATE icon
1
Fate Therapeutics
FATE
$232M
$249M 6.98%
11,216,809
– –
2015 Q2
19 quarters
FOLD icon
2
DELISTED
Amicus Therapeutics
FOLD
$233M 6.52%
25,181,500
-28,464
-0.1% -$271K
2013 Q2
27 quarters
DCPH icon
3
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$211M 5.91%
5,116,263
+406,765
+9% +$22.6M
2017 Q3
10 quarters
BIIB icon
4
Biogen
BIIB
$34.4B
$186M 5.23%
589,300
+131,800
+29% +$40M
2019 Q4
1 quarter
IGMS icon
5
DELISTED
IGM Biosciences
IGMS
$177M 4.95%
3,144,000
– –
2019 Q3
2 quarters
ARGX icon
6
argenx
ARGX
$51.5B
$143M 4%
1,082,070
-71,162
-6% -$10.4M
2017 Q4
9 quarters
MNTA
7
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$141M 3.95%
5,175,008
+1,937,308
+60% +$53.9M
2019 Q4
1 quarter
EPZM
8
DELISTED
Epizyme, Inc
EPZM
$136M 3.81%
8,768,475
+22,442
+0.3% +$482K
2017 Q3
10 quarters
PRNB
9
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$134M 3.76%
2,261,088
-461,300
-17% -$26.9M
2019 Q2
3 quarters
ALLK icon
10
DELISTED
Allakos
ALLK
$132M 3.71%
2,976,928
-56,598
-2% -$3.87M
2018 Q3
6 quarters
QURE icon
11
uniQure
QURE
$1.45B
$132M 3.69%
2,773,525
+220,200
+9% +$12.7M
2018 Q2
7 quarters
APRE icon
12
Aprea Therapeutics
APRE
$7.34M
$78.9M 2.21%
113,436
– –
2019 Q4
1 quarter
RGNX icon
13
Regenxbio
RGNX
$454M
$75.7M 2.12%
2,338,466
-169,920
-7% -$7.08M
2017 Q1
12 quarters
SGEN
14
DELISTED
Seagen Inc. Common Stock
SGEN
$75.7M 2.12%
+655,700
New +$72.6M
2020 Q1
0 quarters
NVRO icon
15
DELISTED
NEVRO CORP.
NVRO
$70.6M 1.98%
706,426
-232,738
-25% -$28M
2019 Q1
4 quarters
MRK icon
16
Merck
MRK
$364B
$60.7M 1.7%
+826,348
New +$64.9M
2020 Q1
0 quarters
BEAM icon
17
Beam Therapeutics
BEAM
$2.44B
$60.5M 1.7%
+3,359,258
New +$73M
2020 Q1
0 quarters
UNH icon
18
UnitedHealth
UNH
$355B
$60.1M 1.69%
241,100
+38,000
+19% +$10.5M
2016 Q3
14 quarters
IMGN icon
19
DELISTED
Immunogen Inc
IMGN
$57.1M 1.6%
16,733,879
+2,093,919
+14% +$9.15M
2017 Q1
12 quarters
TNDM icon
20
Tandem Diabetes Care
TNDM
$1.11B
$56.7M 1.59%
881,266
-290,966
-25% -$20.4M
2018 Q3
6 quarters
ONEM
21
DELISTED
1Life Healthcare
ONEM
$56.7M 1.59%
+3,123,384
New +$68.5M
2020 Q1
0 quarters
NVS icon
22
Novartis
NVS
$279B
$53.9M 1.51%
653,600
+80,500
+14% +$7.18M
2019 Q4
1 quarter
CI icon
23
Cigna
CI
$76.5B
$53.3M 1.49%
300,600
+153,100
+104% +$29.7M
2019 Q4
1 quarter
STOK icon
24
Stoke Therapeutics
STOK
$1.5B
$49.6M 1.39%
2,165,938
+1,145,160
+112% +$28.3M
2019 Q2
3 quarters
CNC icon
25
Centene
CNC
$34.7B
$49M 1.37%
824,090
-728,508
-47% -$44.2M
2019 Q2
3 quarters
1
2 3 4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q1 2020 Portfolio in Review

As of Q1 2020, Redmile Group held 78 positions worth $3.57B, down 15% from $4.18B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Redmile Group's Q1 2020 filing shows 14 new, 15 increased, 33 reduced and 9 closed positions. Its largest new stake was Beam Therapeutics: 3,359,258 shares worth $60.5M. The largest sale was Bristol-Myers Squibb, an estimated $116M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Industrials and Miscellaneous.

  • Redmile Group's largest Q1 2020 buy was Beam Therapeutics: 3,359,258 shares worth $60.5M.
  • Redmile Group added most to Momenta Pharmaceuticals, Inc. in Q1 2020, an estimated $53.9M increase.
  • Redmile Group's biggest Q1 2020 reduction was Centene, cutting an estimated $44.2M.
  • Redmile Group fully exited Bristol-Myers Squibb in Q1 2020, selling an estimated $116M.
  • Redmile Group's ten largest holdings make up 49% of its $3.57B portfolio in Q1 2020.
  • Redmile Group opened 14 new positions and closed 9 in Q1 2020.
  • Redmile Group's portfolio value fell 15% quarter-over-quarter to $3.57B.

Based on Redmile Group's 13F filing for Q1 2020, filed 15 May 2020.